ImmunoScape Announces Three Presentations Highlighting TCR Pipeline and Discovery Platform at the American Association for Cancer Research (AACR) Annual Meeting 2024

SAN DIEGO & SINGAPORE–(BUSINESS WIRE)–ImmunoScape, a biotechnology company focused on next-generation T Cell receptor (TCR)-based immunotherapies, today announced that three abstracts have been accepted for poster presentations at the 2024 American Association for Cancer Research (AACR) Annual Meeting taking place April 5-10, 2024 in San Diego, California.

Presentation details are as follows:

Title: Discovery and development of T cell receptors targeting MAGE family antigens for adoptive T cell therapy against solid tumors
Presenter: Juliana Velez Lujan, Ph.D., ImmunoScape, Senior Scientist
Session Title: Adoptive Cell Therapies 1: Tumor Antigen-Specific T-cells and TCR-T
Date & Time: Sunday, April 7, 2024, 1:30 p.m. – 5:00 p.m. PT
Location: Poster Section 1
Poster Number: 13

Title: Deep Immunomics pipeline for discovery and validation of novel cancer-specific T cell receptors
Presenter: Hannah Fields, ImmunoScape, Scientist
Session Title: Adoptive Cell Therapies 1: Tumor Antigen Specific T-cells and TCR-T
Date & Time: Sunday, April 7, 2024, 1:30 p.m. – 5:00 p.m. PT
Location: Poster Section 1
Poster Number: 8

Title: A validated bioinformatics tool-set for predicting TCR specificity
Presenter: Andreas Wilm, ImmunoScape, Director of Computational Biology
Session Title: Database Resources, Statistical Methods, and Other Tools
Date & Time: Monday, April 8, 2024, 1:30 p.m. – 5:00 p.m. PT
Location: Poster Section 36
Poster Number: 19

Full abstracts are available on the AACR Online Program Planner.

About ImmunoScape

ImmunoScape is a biotechnology company focused on the discovery and development of next-generation TCR cell therapies in the field of oncology. The company’s proprietary Deep Immunomics technology and machine learning platforms enable highly sensitive, large-scale mining and immune profiling of T cells in cancer patient samples to identify novel, therapeutically relevant TCRs across multiple types of solid tumors. ImmunoScape has multiple discovery programs ongoing and will be progressing towards IND-enabling studies and entry into the clinic. For more information, please visit https://immunoscape.com/.